Ep. 182 "The Ins and Outs of JAK Inhibitors for Psoriatic Disease"
Psoriasis Uncovered
00:00
The Role of Janice Tyrosine Kinase in Psoriasis and Arthritis
J&S tyrosine kinase or the Jack family event signs and the development of inflammatory diseases such as psoriasis and psoriatic arthritis. The FDA first approved Jack inhibitors in 2012, a medication called Ruxolitinib was the first Jack inhibitor to be approved then. It is currently used to treat graft versus host disease, myelophbribrosis, and polycythemia there.
Play episode from 01:34
Transcript
